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ABSTRACT: Poly(ADP-ribose) polymerase (PARP) is involved in repair of DNA breaks
and is over-expressed in a wide variety of tumors, making PARP an attractive biomarker for
positron emission tomography (PET) and single photon emission computed tomography
imaging. Consequently, over the past decade, there has been a drive to develop nuclear
imaging agents targeting PARP. Here, we report the discovery of a PET tracer that is based
on the potent PARP inhibitor olaparib (1). Our lead PET tracer candidate, [18F]20, was
synthesized and evaluated as a potential PARP PET radiotracer in mice bearing
subcutaneous glioblastoma xenografts using ex vivo biodistribution and PET−magnetic
resonance imaging techniques. Results showed that [18F]20 could be produced in a good
radioactivity yield and exhibited specific PARP binding allowing visualization of tumors over-
expressing PARP. [18F]20 is therefore a potential candidate radiotracer for in vivo PARP
PET imaging.
■ INTRODUCTION
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear protein
that exhibits a broad range of functions and is involved in
transcription, mitosis, apoptosis, and DNA damage repair.1,2
PARP inhibition has been investigated as a therapeutic
approach to treat cancers by either synthetic lethality in
which tumor cells deficient in a type of DNA repair termed
homologous recombination are sensitized to PARP inhibition,
or chemoradiosensitization, in which PARP inhibition sensitizes
tumor cells to conventional chemo- or radiotherapy. To date,
olaparib (Lynparza), niraparib (Zejula), and rucaparib (Ru-
braca) are the only PARP inhibitors to receive approval for
clinical use in the United States or Europe.3,4 Olaparib (1;
Figure 1) was the first agent in its class to receive such approval.
In the European Union, it is currently indicated for the
treatment of BRCA-mutated (homologous recombination
deficient) ovarian, fallopian-tube, and peritoneal cancers,4 in
which it has been shown to increase progression-free5 and
overall6 survival. In the United States, 1 can also be used for
treatment of BRCA-mutated metastatic breast cancer7 and as a
maintenance therapy for patients with platinum-sensitive
recurrent epithelial ovarian, fallopian-tube, or primary peri-
toneal cancer irrespective of BRCA mutations.8 In both cases, 1
was once again shown to increase progression-free survival.9,10
Olaparib 1 is also being investigated as a radio- and
chemosensitizer for the treatment of solid cancers, including
gliomas. However, adding PARP inhibitors to cytotoxic
chemotherapy agents has been shown to exacerbate bone
marrow toxicity in humans, hindering the establishment of
effective PARP inhibitor and chemotherapy dosage regimens
with acceptable safety profiles.11 In the case of brain tumors,
matters are further complicated as 1 suffers from poor blood−
brain barrier (BBB) permeability, and delivery of the drug to
the tumor is reliant on BBB disruption.12 The degree of BBB
disruption in brain tumors is very variable;13−15 this could affect
tumor penetration by 1 and, hence, reduce the clinical
effectiveness of PARP inhibitor therapy. Furthermore, in vivo
animal studies have revealed that prolonged treatment with 1
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Figure 1. PARP inhibitor olaparib.
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can result in increased tumor P-glycoprotein efflux transporter
expression and subsequent drug resistance.16
The above-mentioned issues highlight the challenges that are
associated with PARP inhibitor therapy in the context of
synthetic lethality as well as chemo- and radiosensitization.
Nuclear imaging of an appropriately radiolabeled PARP
inhibitor could be used to overcome these challenges. In
combination with a suitable blockade study protocol, nuclear
imaging could indirectly establish the distribution and retention
of PARP inhibitors in tumors and normal tissues and
subsequently identify therapeutic dosage regimens for which
the combination of PARP inhibitors and cytotoxic agents exerts
maximal tumor and minimal bone marrow cytotoxicity.
Furthermore, a radiolabeled PARP probe could be used to
indirectly ascertain the occupancy, retention, and target
engagement of 1 in brain tumor tissue. This type of approach
has been successfully applied in preclinical models of small-cell
lung17 and epithelial ovarian cancer.18 In a clinical setting, this
could be used to identify patients that are unlikely to respond
to PARP inhibitor therapy due to weak target engagement as a
consequence of poor drug tumor uptake or resistance caused by
efflux transporter over-expression.
Previously, we reported the synthesis and characterization of
a [123I]-labeled compound with potential for single-photon
emission computed tomography (SPECT) imaging of PARP.19
Despite the established nature of the SPECT imaging modality,
the use of positron emission tomography (PET) is rapidly
expanding and, in many cases, has become the preferred
nuclear imaging modality in the clinic. This can be attributed to
the superior spatial resolution,20 quantification, and sensitivity21
of PET compared to SPECT. It is, therefore, not surprising that
many of the current nuclear imaging agents for PARP were
designed with PET imaging in mind (Figure 2).22,23
Importantly, the rationale for developing PARP PET imaging
agents has been recently solidified by [18F]4, which was shown
to be capable of noninvasively ascertaining PARP-1 expression
in epithelial ovarian tumors in humans.18,24
Here, we report the synthesis of a small library of fluorinated
analogs of the clinical PARP inhibitor 1 with potential for
PARP PET imaging and the in vitro characterization of these
compounds. The lead analog 20 was synthesized in its
radiofluorinated version and evaluated as a potential PARP
PET radiotracer in mice bearing subcutaneous glioblastoma
xenografts using ex vivo biodistribution and PET−magnetic
resonance (MR) imaging techniques.
■ RESULTS AND DISCUSSION
Chemistry and in Vitro Characterization. Due to poor
accessibility of the central ring fluorine atom of 1 for
radiolabeling,25 focus was directed at synthesizing analogs of
1 bearing distal fluorinated moieties that were more likely to be
amenable to radiofluorination methods. Initially, six fluorinated
PARP inhibitors (8−13) containing the characteristic phthala-
zinone scaffold were synthesized through amide or N-alkyl
coupling of commercially available benzoic carboxylic acids or
benzyl halides with piperazine 7, the synthesis of which we
described previously19 (Table 1). The structures of compounds
8−13 were confirmed in part by nuclear magnetic resonance
(NMR) spectroscopic analysis, which showed that the majority
of these exist as a mixture of amide rotamers. The design of
these analogs was partly driven by previous reports,25−27 which
have shown that structural modifications can be performed in
the cyclopropane bearing region of 1 without having a marked
effect on PARP inhibition. To confirm this, cell-free PARP-1
IC50 assays were performed on compounds 8−13, and the
results of these experiments were compared against the cell-free
IC50 of 1 (Table 1). Compared to 1, all compounds showed
improved PARP-1 potency except for compound 13, which had
an overlapping cell-free IC50 95% confidence interval.
Compounds 8−13 were also evaluated for their lipophilic
and plasma protein binding properties, defined by log Poct and
percentage plasma protein binding (%PPB) parameters (Table
1). All six analogs exhibited greater log Poct and %PPB values in
comparison to 1. This may be attributed to the addition of
aromatic and methyl moieties, which have the potential to
increase lipophilicity and can, in turn, result in an increased %
PPB due to the hydrophobic nature of plasma protein
interactions.28 From the perspective of nuclear imaging,
radiotracers with high log Poct (>3.0)
29 and %PPB (>95%)30
values can be associated with poor passive diffusion across
biological membranes and vascular retention, which can in turn
result in a poor target to background signal ratio. The
physiochemical parameters of 8−12 were all found to be
within the optimal range for radiotracer development.
Figure 2. Published examples of PARP PET radiotracers.22,23
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However, following analysis of the established in vitro
parameters and potential radiochemical accessibility, compound
8 was identified as an initial lead candidate for further
advancement in this research program. To establish the
potency of 8 against PARP in living cells, cellular IC50 assays
were performed using primary (G7) and secondary (T98G)
human glioblastoma cell lines (Table 2) and previously
described methodology.19 Compound 8 exhibited low nano-
molar IC50 values that were in line with those observed for 1 in
both cell lines, suggesting that 8 was able to effectively
penetrate cellular membranes and reach PARP localized within
cellular nuclei.
To access the [18F]-radiofluorine analog of 8, standard
aromatic nucleophilic substitution chemistry was employed
using p-nitrobenzamide precursor 14, which was generated
through amide coupling of 7 with commercially available 4-
nitrobenzoic acid (Scheme 1). However, optimization of the
radiofluorination step proved challenging (see the Supporting
Information), and the maximum radiochemical yield (based on
high-performance liquid chromatography [HPLC] analysis of
crude product) achieved was only 19% (Scheme 1). It was
proposed that the poor yield was a consequence of a lack of
activation of the system for aromatic nucleophilic substitution
due to the weak electron withdrawing properties of the amide
located para- to the nitro leaving group. Since commencing this
work, Carney et al. were able to synthesize [18F]8 with an
optimized radioactivity yield of 38 ± 2.5% (isolated product)
Table 1. Methods Used to Generate Analogs 8−13 from the Penultimate Compound 7 as well as the Cell-Free PARP-1
Inhibitory and Physiochemical Properties of 1 and 8−13
aCell-free IC50 values are based on three experiments.
bLipophilicity (log Poct) was determined using a C-18 reverse-phase HPLC column.
cPercentage plasma protein binding (%PPB) was determined using a human serum albumin coated HPLC column. Reagents and conditions for
reaction below the table title: (a) HBTU, Et3N, DMF, room temperature (rt), 72 h; (b) HBTU, DIPEA, CH2Cl2, rt, 24 h; (c) EDCl, DMAP,
CH2Cl2, rt then reflux, 24 h; (d) HBTU, DIPEA, DMF, 50 °C, 24 h; (e) DIPEA, CH2Cl2, rt, 24 h.
Table 2. Cellular PARP Inhibitory Properties of Compounds
1 and 8
cellular IC50 (95% CI), nM
a
compound G7 T98G
1 1.6 (1.4−1.8) 1.6 (1.4−1.8)
8 1.0 (0.9−1.2) 0.8 (0.7−0.9)
aCellular IC50 values obtained using primary G7 and established T98G
human glioblastoma cell lines are based on two experiments.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00138
J. Med. Chem. 2018, 61, 4103−4114
4105
using a multistep early-stage radiofluorination approach that
circumvented the aforementioned issue of poor activation.17
Therefore, our attention was redirected toward an alternative
target compound, 20, bearing a p-(fluoromethyl)benzamide
group. It was proposed that a precursor analog of 20 would be
more amenable to radiofluorination than p-nitrobenzamide 14,
thereby allowing for late-stage radiofluorination and radio-
synthetic automation. Compound 20 was synthesized by first
performing an amide coupling reaction between mono-Boc
protected piperazine 15 and commercially available 4-
(chloromethyl)benzoic acid, giving access to intermediate 16
in 40% yield (Scheme 2). p-Chlorobenzamide 16 was then
subjected to nucleophilic fluorination with tetra-n-butylammo-
nium fluoride (TBAF), and this was followed by acid-mediated
cleavage of the Boc-protecting group to give 18 in 87% yield
over two steps. Finally, reaction of carboxylic acid 19,
previously synthesized within our research group,19 and
piperazine 18 under standard amide coupling conditions gave
target 20. The log Poct, %PPB, and cell-free and cellular IC50
values were established for 20 in the same manner as described
for the other analogs (8−13) in this series (Table 3).
As expected, compound 20 exhibited higher log Poct and
%PPB values than 1 (Table 3). However, these were still within
the optimal range for a nuclear imaging agent. Interestingly,
despite 20 having an identical log Poct value to 8, the former
compound exhibited a higher degree of %PPB. Furthermore,
Scheme 1. Radiofluorination Approach Used to Generate [18F]8 From the Nitro Precursor 14
aRadiochemical yield was determined by radio-HPLC analysis of the crude product.
Scheme 2. Synthetic Route Used to Generate Compound 20
Table 3. Physiochemical, Cell-Free PARP-1 and Cellular PARP Inhibitory, and Mouse Plasma and Metabolic Stability
Properties of 1 and 20
cellular IC50 (95% CI), nM
d
plasma
stability,
percente Clint, μL min
−1mg−1f
compound log Poct
a %PPBb cell-free IC50 (95% CI), nM
c G7 T98G 0 h 20 h experiment 1 experiment 2
1 1.95 75.9 11.9 (10.5−13.6) 1.6 (1.4−1.8) 1.6 (1.4−1.8) − − 23 34
20 2.51 89.3 2.0 (1.9−2.2) 1.3 (0.7−2.3) 2.0 (1.3−3.1) 93 95 74 90
aLipophilicity (log Poct) was determined using a C-18 reverse-phase HPLC column.
bPercentage plasma protein binding (%PPB) was determined
using a human serum albumin coated HPLC column. cCell-free IC50 values are based on three experiments.
dCellular IC50 values obtained using
primary G7 and established T98G human glioblastoma cell lines are based on two experiments. eThe mean percentage of parent compound
remaining after a 20 h incubation in mouse plasma (±SD of 3 experiments) was ascertained for compound 20. fIntrinsic clearance (Clint) values of
two independent experiments acquired using human liver microsomes.
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compound 20 had a cell-free IC50 value that was 6- and 3-fold
less than that acquired for 1 and 8, respectively. Conversely, the
cellular PARP inhibitory properties of 20 were comparable to
compound 1 and marginally weaker than ascertained for
compound 8. Collectively, the optimal physiochemical proper-
ties and low nanomolar PARP cell-free and cellular IC50 values
supported further investigation of 20 as a potential radiotracer
for PARP. In the body, radiotracers can be exposed to a number
of metabolic pathways, including blood plasma hydrolysis and
liver functionalization or conjugation reactions that can have a
significant effect on the kinetic properties of the tracer and,
subsequently its usefulness in nuclear imaging. With this in
mind, the in vitro plasma and liver microsome stability of lead
candidate 20 were established by incubating the compound in
mouse plasma proteins and human liver microsome enzymes,
respectively, using previously described methodologies.19
Candidate 20 appeared stable in mouse plasma with negligible
decomposition following a 20 h incubation (Table 3).
However, the intrinsic clearance parameter (a predictor of
phase I liver metabolism) was approximately 3-fold greater for
compound 20 in comparison to 1. Despite this, it was proposed
that compound 20 would exhibit sufficient tissue retention to
allow for nuclear imaging of PARP. This was justified by
previously acquired data using a radioiodinated p-iodobenza-
mide analog that exhibited similar in vitro intrinsic clearance
properties to 20 but still displayed a degree of retention in
PARP over-expressing tumor tissue.19
Initial attempts to generate the radiofluorinated version of 20
involved performing nucleophilic substitution reactions be-
tween the 18F− nucleophile and the chloromethyl group of
precursor 21, which was obtained by amide coupling of 7 with
commercially available 4-(chloromethyl)benzoic acid (Scheme
3). However, these attempts were not successful because
competing oligomerization reactions between the chloromethyl
group of 21 and the phthalazinone core prevented effective
radiofluorination. To overcome this issue, the phthalazinone
core of 21 was Boc-protected to give compound 22.
Precursor 22 was then subjected to a screen of radio-
fluorination conditions as outlined in Table 4. The radio-
chemical yield (based on HPLC analysis of the crude product)
was 30% when tetra-n-butylammonium hydrogen carbonate
(TBAHCO3) was used as a phase-transfer agent, which was
markedly higher in comparison to that obtained for Kryptofix
(K222) (entries 1 and 2). It has been reported in the literature
that the introduction of a sterically hindered protic alcohol can
have a beneficial effect on aliphatic nucleophilic radio-
fluorination reactions.31,32 With the use of a 2:1 mixture of t-
BuOH and MeCN as the reaction solvent, the radiofluoride
incorporation increased from 30% to 48% in comparison to the
same volume of MeCN alone (entries 1 and 3). A 30 min
reaction time was established to be optimal based on lower
radiochemical yields observed after a shorter reaction time
(entry 4) and the short-lived nature of the 18F radioisotope
(half-life of 109.8 min), which prevented longer reaction
periods. Radiofluoride incorporation was further improved by
increasing the reaction temperature from 100 to 110 °C, which
resulted in a 51% radiochemical yield (entry 5). Interestingly,
doubling the reaction solvent volume had a negative impact on
the degree of radiofluorination (entry 6). Based on these data,
the reaction conditions described in entry 5 were deemed
optimal.
To access [18F]20, compound [18F]23 was subjected to Boc
deprotection, which was achieved in 5 min and with minimal
defluorination taking place by using water as an acid−base
catalyst (Scheme 4). The use of hydrochloric acid was also
investigated as a deprotecting agent, but its use was associated
with marked defluorination (see the Supporting Information).
The optimized two-step one-pot radiochemical reaction
allowed access to [18F]20 in a radioactivity yield (isolated
product) of 9 ± 2% (n = 7) and a molar activity of >4.32 ±
1.46 Ci μmol−1 (n = 3). Importantly, the one-pot nature of the
reaction opens up the potential for radiosynthetic automation.
In Vivo Characterization. Following successful optimiza-
tion of the radiochemistry, the behavior of [18F]20 was
investigated in vivo in mice bearing subcutaneous U87MG-
Luc2 human glioblastoma tumor xenografts using ex vivo
biodistribution and PET−MR imaging techniques. Ex vivo
biodistribution of [18F]20 was established at 30, 60, and 120
min after intravenous radiotracer administration, and PET data
were acquired by performing a 45 min dynamic scan. These
experiments showed that a large proportion of radioactivity was
detectable in the liver and small bowel at 30−45 min post tracer
administration (Figure 3a,b) and mostly concentrated in the
cecum matter and solid feces after 120 min (Figure 3a). This is
in line with our previous findings19 and other literature
reports,25,33,34 which showed in vivo hepatobiliary clearance of
a range of related radioiodinated and radiofluorinated
compounds based on the structure of 1. Interestingly, the
mean percentage of injected dose per gram (%ID/g) of femur
tissue remained relatively high across all three biodistribution
time points (i.e., >8.5%; Figure 3a), which was also confirmed
by PET imaging, in which high skeletal uptake of radioactivity
was visible (Figure 3b). This is in contrast to observations made
by Carney et al., who reported <2%ID/g of bone of [18F]8 at
120 min.34 The high bone uptake seen with [18F]20 could be
explained by in vivo defluorination and subsequent radio-
fluoride accumulation in bone tissue.35 Despite this, apparent
radiotracer tumor uptake was identified in both biodistribution
and PET−MR imaging experiments (Figures 3a,c), whereas in
the case of the former, the mean ratio of %ID/g of glioblastoma
tumor to muscle increased from 1.9 ± 0.5 (n = 4) to 3.6 ± 0.5
(n = 4) between the 30 and 120 min time points. This was
Scheme 3. Synthetic Route Used to Generate p-
Chloromethylbenzamide Precursor 22
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suggestive of [18F]20 retention in U87Mg-Luc2 glioblastoma
tissue, which we have shown to be highly proliferative (see the
Supporting Information) and to over-express PARP relative to
muscle tissue (Figure 3d).
To establish the specificity of [18F]20 for PARP in bone and
tumor tissue, further biodistribution studies were performed on
subcutaneous U87MG-Luc2 glioblastoma bearing mice that
had PARP binding sites blocked by pretreatment with
nonradioactive compound 1 at a dose of 50 mg/kg 20 min
prior to [18F]20 administration. The uptake of [18F]20 in bone
tissue remained high 60 min after radioligand administration
and was not influenced by the presence of excess non-
radioactive 1 (Figure 3e). This supports the earlier proposed
possibility of in vivo [18F]20 defluorination, leading to free
radiofluoride accumulation in the bone. Despite this,
preblockade using 1 resulted in a statistically significant
decrease in the ratio of %ID/g of tumor to muscle from 1.79
± 0.39 (n = 4) to 1.07 ± 0.15 (n = 4) 60 min after [18F]20
administration in comparison to vehicle-pretreated mice
(unpaired t-test: P < 0.05). These findings suggested that the
uptake of [18F]20 in tumor was due to specific PARP binding,
which was in line with our previous findings for a related
radioiodinated analog of 1.19
■ CONCLUSIONS
We described here the identification and one-pot manual
radiosynthesis of a PARP PET imaging agent, [18F]20, that was
accessed in good radioactivity yield and showed desirable
physiochemical properties but suffered from rapid hepatobiliary
clearance and in vivo defluorination followed by nonspecific
18F− bone tissue uptake in mice. Despite this, the radiotracer
compound exhibited specific PARP binding and subcutaneous
glioblastoma tumor retention properties, which allowed for
preclinical PET visualization of the PARP over-expressing
tumor. Therefore, we believe that [18F]20 should remain a
potential candidate radiotracer for in vivo PARP PET imaging
and that future imaging studies using small-animal intracranial
glioblastoma models are required to further assess the utility of
this compound.
■ EXPERIMENTAL SECTION
All reagents and starting materials were obtained from commercial
sources and used as received. Dry solvents were purified using a
solvent purification system, and all reactions were performed under an
atmosphere of argon unless stated otherwise. Macherey-Nagel
aluminum-backed plates precoated with silica gel 60F254 were used
for thin layer chromatography and were visualized with a UV lamp.
Flash column chromatography was performed using Fisher matrix
silica gel 60 (35−70 μm). 1H NMR spectra were recorded on a Bruker
DPX 400 or Bruker 500 spectrometer, and data are reported as
follows: chemical shift in parts per million (ppm) relative to Me4Si or
the solvent (CDCl3, δ 7.26 ppm; CD3OD, δ 3.31 ppm; or dimethyl
sulfoxide [DMSO-δ6] δ, 2.50 ppm) as the internal standard,
multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet
or overlap of nonequivalent resonances, integration). 13C NMR
Table 4. Optimization of the Nucleophilic Halogen Exchange Methodology Used to Access Intermediate [18F]23 from the
Chloro Precursor 22
entry solvent (volume, mL) PTAa temperature, °C reaction time, min radiochemical yield, percentb
1 MeCN (0.3) TBAHCO3 100 30 30
2 MeCN (0.3) K222 100 30 4
3 MeCN (0.1)/ tBuOH (0.2) TBAHCO3 100 30 48
4 MeCN (0.1)/ tBuOH (0.2) TBAHCO3 100 10 22
5 MeCN (0.1)/ tBuOH (0.2) TBAHCO3 110 30 51
6 MeCN (0.2)/ tBuOH (0.4) TBAHCO3 110 30 37
aPTA: phase-transfer agent. bRadiochemical yields were determined by radio-HPLC analysis of the crude product from a single reaction.
Scheme 4. Optimized Radiofluorination Approach Used to Generate [18F]20
aRadioactivity yield was determined using the measured radioactivity of the isolated product.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00138
J. Med. Chem. 2018, 61, 4103−4114
4108
spectra were recorded on a Bruker DPX NMR spectrometer at either
101 or 126 MHz, and data are reported as follows: chemical shift
(ppm) relative to Me4Si or the solvent as internal standard (CDCl3, δ
77.2 ppm; CD3OD, δ 49.0 ppm; or DMSO-δ6, δ 39.5 ppm),
multiplicity with respect to proton (deduced from DEPT experiments;
C, CH, CH2, or CH3). Infrared spectra were recorded using a
Shimadzu IRPrestige-21 spectrometer; wavenumbers are indicated
with units of cm−1. Mass spectra were recorded using electron impact,
chemical ionization, or electrospray techniques. High-resolution mass
spectrometry (HRMS) results were recorded using a JEOL JMS-700
spectrometer. Melting points are uncorrected. All compounds used for
biological testing exhibited >95% purity as per HPLC. Purity
assessment of compounds 8−13 was performed by injecting 0.5−1.5
mg/mL of sample of interest in 1:1 MeCN and 0.01 mM PBS (pH
7.4) onto a reverse-phase Phenomenex Luna 5 μm C18 100 Å (50 mm
× 30 mm) column under the following mobile-phase conditions: 0.0−
10.5 min, 100:0 to 10:90 A/B; 10.5−11.5 min, 10:90 A/B; and 11.5−
12.0 min, 10:90 to 100:0 A/B, where A is PBS (pH 7.4) and B is
MeCN. The mobile-phase flow rate was 1.0 mL/min, and the column
temperature was set to 25 °C. Analytical UV detection was performed
using a UltiMate diode array detector (190−800 nm). Purity
assessment for compound 20 was performed as described above
using the following mobile-phase conditions: 0.0−15.0 min 70:30 to
5:95 A/B, where A is PBS (pH 7.4) and B is MeCN. Mice used for in
vivo studies were housed in individually ventilated cages and had
access to sterilized food and water ad libitum. All animal experiments
were carried out in compliance with UK Home Office regulations. The
synthesis of compounds 1, 7, and 15 has been reported previously.19
4-[3′-[4″-(4‴-Fluorobenzoyl)piperazine-1″-carbonyl]-4′-flu-
orobenzyl]-2H-phthalazin-1-one (8). To a solution of 4-
fluorobenzoic acid (0.029 g, 0.21 mmol) in dichloromethane (5 mL)
was added N,N-diisopropylethylamine (DIPEA; 60.8 μL, 0.349 mmol)
followed by 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hex-
afluorophosphate (HBTU; 0.080 g, 0.21 mmol), and the mixture was
stirred vigorously under reflux for 1 h. Following this, 7 (0.064 g, 0.17
mmol) was added, and the mixture was stirred for a further 24 h. On
cooling to ambient temperature, water (5 mL) was added and the
organic layer washed with water (3 × 10 mL) and a saturated
NaHCO3 solution (10 mL), dried with MgSO4, filtered, and
concentrated in vacuo. Purification using flash column chromatog-
raphy (MeOH/CH2Cl2, 3:97) gave 8 (0.064 g, 75%) as a white solid;
mp 166−168 °C; IR (neat): 3202, 2922, 1629, 1425, 1285, 1223,
1152, 1005, 847 cm−1; 1H NMR (400 MHz, CDCl3, δ): 3.20−4.05 (m,
8H), 4.29 (s, 2H), 6.98−7.14 (m, 3H), 7.30−7.45 (m, 4H), 7.68−7.79
(m, 3H), 8.45−8.49 (m, 1H), 11.37 (s, 1H); 13C NMR (101 MHz,
CDCl3, δ): 37.7 (CH2), 42.1 (2 × CH2), 47.0 (2 × CH2), 115.8 (2 ×
CH, d, JC−C−F = 21.9 Hz), 116.2 (CH, d, JC−C−F = 22.0 Hz), 123.6 (C,
d, JC−C−F = 17.8 Hz), 125.0 (CH), 127.2 (CH), 128.3 (C), 129.3 (CH,
d, JC−C−C−F = 3.5 Hz), 129.5 (2 × CH, d, JC−C−C‑F = 8.7 Hz), 131.1 (C,
d, JC−C−C−C−F = 3.5 Hz), 131.6 (CH), 131.8 (CH, d, JC−C−C−F = 8.0
Hz), 133.7 (CH), 134.5 (C, d, JC−C−C−C−F = 3.5 Hz), 145.5 (C), 157.0
(C, d, JC−F = 247.4 Hz), 160.8 (2 × C), 163.6 (C, d, JC−F = 250.7 Hz),
165.2 (C), 169.7 (C); HRMS (ESI): [MNa+] calcd for
C27H22F2N4NaO3, 511.1552; found, 511.1547.
4-[3′-[4″-(2‴-Fluorobenzoyl)piperazine-1″-carbonyl]-4′-flu-
orobenzyl]-2H-phthalazin-1-one (9). The reaction was carried out
as described for 8 using 2-fluorobenzoic acid (0.047 g, 0.34 mmol),
DIPEA (97.0 μL, 0.557 mmol), HBTU (0.127 g, 0.334 mmol), and 7
(0.102 g, 0.278 mmol) in dichloromethane (10 mL). Purification using
flash column chromatography (MeOH/CH2Cl2, 3:97) gave 9 (0.072 g,
53%) as a white solid. NMR spectra showed a 56:44 mixture of
rotamers. Only the data for the major rotamer were recorded; mp
246−248 °C; IR (neat): 3043, 2894, 1684, 1641, 1464, 1433, 1289,
1251, 1007, 775 749 cm−1; 1H NMR (CDCl3, 400 MHz) δ 3.20−4.10
(m, 8H), 4.30 (s, 2H), 6.96−7.50 (m, 7H), 7.67−7.81 (m, 3H), 8.42−
8.49 (m, 1H), 10.17 (br s, 1H); 13C NMR (CDCl3, 101 MHz) δ 37.7
(CH2), 41.8 (CH2), 42.2 (CH2), 46.8 (CH2), 47.4 (CH2), 115.9 (CH,
d, JC−C−F = 21.4 Hz), 116.1 (CH, d, JC−C−F = 20.4 Hz), 123.4 (C, d,
JC−C−F = 17.8 Hz), 123.7 (C, d, JC−C−F = 18.3 Hz), 125.0 (CH), 125.0
(2 × CH), 127.3 (CH), 128.4 (C), 129.3 (CH), 129.5 (C), 131.7
(CH), 131.8 (CH), 131.9 (CH), 133.7 (2 × CH), 134.4 (C), 145.5
(C), 157.1 (C, d, JC−F = 247.5 Hz), 158.1 (C, d, JC−F = 247.8 Hz),
Figure 3. (a) Ex vivo biodistribution of [18F]20 in subcutaneous human U87MG-Luc2 glioblastoma bearing nude mice 30 min (n = 4), 60 min (n =
4), and 120 min (n = 4) after tracer injection (error bars represent the mean percentage of injected dose per gram of tissue or material (% ID/g) plus
SD). (b) Mouse whole-body maximum intensity projection. (c) 1T GRE 3D coronal and sagittal MRI, PET, and PET−MR co-registered images of a
nude mouse bearing a subcutaneous U87MG-Luc2 human glioblastoma (white arrows) acquired by performing a 45 min dynamic scan following
[18F]20 administration (PET images represent a summation of the last 15 min of the scan). (d) Representative immunohistochemistry images of
U87MG-Luc2 subcutaneous tumor and muscle tissue isolated from nude mice stained for PARP-1 and counter-stained with hematoxylin (brown
staining signifies the presence of PARP-1, and dark blue staining shows cellular nuclei). (e) Ratio of percentage of injected dose per gram (%ID/g) of
tissue of interest to muscle of [18F]20, 60 min after injection in subcutaneous U87MG-Luc2 human glioblastoma bearing nude mice pretreated with
either vehicle (n = 3) or 50 mg/kg of 1 (n = 3) (error bars represent the mean plus SD; unpaired t-test: P < 0.05).
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160.1 (C), 165.2 (C), 165.5 (C); HRMS (ESI): [MNa+] calcd for
C27H22F2N4NaO3, 511.1552; found, 511.1545.
4-[3′-[4″-(4‴-Fluoro-2‴-methylbenzoyl)piperazine-1″-car-
bonyl]-4′-fluorobenzyl]-2H-phthalazin-1-one (10). To a solution
of 4-fluoro-2-methylbenzoic acid (0.042 g, 0.27 mmol) in dichloro-
methane (5 mL) was added EDCI (0.052 g, 0.27 mmol), and the
reaction mixture was stirred at ambient temperature for 0.5 h. 4-
Dimethylaminopyridine (DMAP; 0.017 g, 0.14 mmol) was then added
and the mixture was stirred for a further 0.5 h. A solution of 7 (0.100 g,
0.273 mmol) in dichloromethane (5 mL) was then added drop-wise
and the resultant reaction mixture stirred vigorously under reflux for
24 h. Upon cooling to ambient temperature, water (5 mL) was added
and the organic layer washed with water (3 × 5 mL) and a NaHCO3
solution (5 mL), dried with MgSO4, filtered, and concentrated in
vacuo. Purification using flash column chromatography (MeOH/
CH2Cl2, 1:49) gave 10 (0.043 g, 31%) as a white solid. NMR spectra
showed a 59:41 mixture of rotamer. Only data for the major rotamers
were recorded; mp 175−177 °C; IR (neat): 3188, 2926, 1632, 1462,
1429, 1256, 1159, 1003, 772, 727 cm−1; 1H NMR (400 MHz, CDCl3,
δ): 2.32 (s, 3H), 3.15−3.45 (m, 4H), 3.55−4.10 (m, 4H), 4.30 (s, 2H),
6.85−7.18 (m, 4H), 7.26−7.39 (m, 2H), 7.67−7.81 (m, 3H), 8.43−
8.50 (m, 1H), 10.30 (s, 1H); 13C NMR (126 MHz, CDCl3, δ): 19.2
(CH3), 37.7 (CH2), 41.8 (CH2), 42.4 (CH2), 46.5 (CH2), 46.9 (CH2),
113.2 (CH, d, JC−C−F = 21.5 Hz), 116.3 (CH, d, JC−C−F = 20.6 Hz),
117.5 (CH, d, JC−C−F = 21.1 Hz), 123.6 (C, d, JC−C−F = 17.0 Hz),
125.0 (CH), 127.2 (CH), 127.8 (CH, d, JC−C−C‑F = 8.6 Hz), 128.3
(C), 129.3 (CH, d, JC−C−C‑F = 3.2 Hz), 129.6 (C), 131.5 (C, d,
JC−C−C−C−F = 7.3 Hz), 131.6 (CH), 131.8 (CH), 133.7 (CH), 134.5
(C, d, JC−C−C−C−F = 3.4 Hz), 137.4 (C, d, JC−C−C−F = 8.1 Hz), 145.5
(C), 157.0 (C, d, JC−F = 246.4 Hz), 160.7 (C), 162.9 (C, d, JC−F =
248.8 Hz), 165.3 (C), 169.6 (C); HRMS (ESI): [MNa+] calcd for
C28H24F2N4NaO3, 525.1709; found, 525.1696.
4-[3′-[4″-[(4‴-Fluorophenyl)acetyl]piperazine-1″-carbonyl]-
4′-fluorobenzyl]-2H-phthalazin-1-one (11). To a solution of 4-
fluorophenylacetic acid (0.043 g, 0.28 mmol) in dimethylformamide
(DMF; 5 mL) was added DIPEA (93.4 μL, 0.546 mmol) followed by
HBTU (0.105 g, 0.277 mmol), and the reaction mixture was stirred
vigorously at ambient temperature for 1 h. A solution of 7 (0.100 g,
0.273 mmol) in DMF (5 mL) was then added drop-wise, and the
resultant reaction mixture heated to and stirred at 50 °C for a further
24 h. The crude reaction mixture was worked up as described for as
described for 8. Purification using flash column chromatography
(MeOH/CH2Cl2, 1:24) gave 11 (0.063 g, 46%) as white solid. NMR
spectra showed a 57:43 mixture of rotamers. Only data for the major
rotamer were recorded; mp 216−218 °C; IR (neat): 2899, 2346, 1636,
1586, 1508, 1431, 1219, 1157, 1011 cm−1; 1H NMR (400 MHz,
CDCl3, δ): 3.03−3.85 (m, 10H), 4.28 (br s, 2H), 6.95−7.07 (m, 3H),
7.13−7.24 (m, 2H), 7.27−7.36 (m, 2H), 7.66−7.79 (m, 3H), 8.44−
8.49 (m, 1H), 11.01 (s, 1H); 13C NMR (101 MHz, CDCl3, δ): 37.7
(CH2), 39.9 (CH2), 42.0 (2 × CH2), 45.7 (CH2), 46.7 (CH2), 115.7
(2 × CH, d, JC−C−F = 21.4 Hz), 116.2 (CH, d, JC−C−F = 22.0 Hz),
123.5 (C, d, JC−C−F = 17.6 Hz), 125.0 (CH), 127.2 (CH), 128.3 (C),
129.2 (CH, d, JC−C−C‑F = 2.3 Hz), 129.5 (C), 130.2 (C), 130.2 (2 ×
CH, d, JC−C−C‑F = 7.9 Hz), 131.6 (CH), 131.8 (CH, d, JC−C−C‑F = 8.1
Hz), 133.7 (CH), 134.5 (C, d, JC−C−C−C‑F = 3.4 Hz), 145.5 (C), 157.0
(C, d, JC−F = 247.6 Hz), 160.8 (C), 161.9 (C, d, JC−F = 247.6 Hz),
165.2 (C), 169.6 (C); HRMS (ESI): [MNa+] calcd for
C28H24F2N4NaO3, 525.1709; found, 525.1705.
4-[3′-[4′′′′′-[(4‴-Fluorophenyl)butane-1⁗,4⁗-dione]-piper-
azine-1‴-carbonyl]4″-fluorobenzyl]-2H-phthalazin-1-one (12).
The reaction was carried out as described for 10 using 3-(4-
fluorobenzoyl)propionic acid (0.053 g, 0.27 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI; 0.052 g, 0.27 mmol),
DMAP, and 7 (0.100 g, 0.273 mmol) in dichloromethane (10 mL).
Purification using flash column chromatography (MeOH/CH2Cl2,
1:24) gave 12 (0.050 g, 34%) as a pale yellow solid. NMR spectra
showed a 56:44 mixture of rotamers. Only data for the major rotamer
were recorded; mp 128−130 °C; IR (neat): 3208, 2909, 1636, 1595,
1433, 1356, 1225, 1155, 1011 cm−1; 1H NMR (400 MHz, CDCl3, δ):
2.82 (t, J = 6.4 Hz, 2H), 3.24−3.46 (m, 4H), 3.50−3.98 (m, 6H), 4.28
(s, 2H), 7.05 (t, J = 8.8 Hz, 1H), 7.10−7.16 (m, 2H), 7.30−7.39 (m,
2H), 7.68−7.81 (m, 3H), 8.00−8.06 (m, 2H), 8.44−8.49 (m, 1H),
10.33 (s, 1H); 13C NMR (101 MHz, CDCl3, δ): 27.0 (CH2), 33.4
(CH2), 37.7 (CH2), 42.0 (CH2), 42.1 (CH2), 45.1 (CH2), 46.8 (CH2),
115.7 (2 × CH, d, JC−C−F = 21.8 Hz), 116.2 (CH, d, JC−C−F = 21.9
Hz), 123.7 (C, d, JC−C−F = 17.6 Hz), 125.0 (CH), 127.2 (CH), 128.3
(C), 129.2 (CH, d, JC−C−C−F = 3.0 Hz), 129.6 (C), 130.8 (2 × CH, d,
JC−C−C−F = 9.4 Hz), 131.6 (CH), 131.7 (CH, d, JC−C−C−F = 8.0 Hz),
133.2 (C), 133.6 (CH), 134.5 (C, d, JC−C−C−C−F = 3.3 Hz), 145.5 (C),
157.0 (C, d, JC−F = 247.4 Hz), 160.7 (C), 165.3 (C), 165.8 (C, d, JC−F
= 254.8 Hz), 170.5 (C), 197.4 (C); HRMS (ESI): [MNa+] calcd for
C30H26F2N4NaO4, 567.1814; found, 567.1796.
4-[3′-[4″-(4‴-Fluorobenzyl)piperazine-1″-carbonyl]-4′-fluo-
robenzyl]-2H-phthalazin-1-one (13). To a stirred solution of 7
(0.023 g, 0.063 mmol) in dichloromethane (3 mL) was added 4-
fluorobenzyl chloride (7.9 μL, 0.066 mmol) followed by DIPEA (21.9
μL, 0.126 mmol). The resultant reaction mixture was stirred at
ambient temperature for 12 h, and then water (5 mL) was added. The
mixture was washed with water (2 × 5 mL) and the organic layer was
dried with MgSO4, filtered, and concentrated in vacuo. Purification
using flash column chromatography (MeOH/CH2Cl2, 1:9) gave 13
(0.011 g, 38%) as an off-white solid; mp 109−111 °C; IR (neat): 3185,
2916, 1637, 1508, 1437, 1348, 1221, 1148, 999 cm−1; 1H NMR (400
MHz, CDCl3, δ): 2.34 (br s, 2H), 2.50 (t, J = 5.2 Hz, 2H), 3.28 (br s,
2H), 3.48 (s, 2H), 3.75−3.82 (m, 2H), 4.28 (s, 2H), 6.96−7.04 (m,
3H), 7.24−7.34 (m, 4H), 7.69−7.78 (m, 3H), 8.44−8.50 (m, 1H),
10.86 (s, 1H); 13C NMR (101 MHz, CDCl3, δ): 37.8 (CH2), 42.0
(CH2), 47.1 (CH2), 52.5 (CH2), 53.0 (CH2), 62.0 (CH2), 115.2 (2 ×
CH, d, JC−C−F = 21.2 Hz), 116.1 (CH, d, JC−C−F = 21.8 Hz), 124.3 (C,
d, JC−C−F = 18.3 Hz), 125.1 (CH), 127.2 (CH), 128.3 (C), 129.1 (CH,
d, JC−C−C−F = 3.8 Hz), 129.6 (C), 130.5 (2 × CH, d, JC−C−C−F = 7.9
Hz), 131.2 (CH, d, JC−C−C−F = 7.9 Hz), 131.6 (CH), 133.3 (C, d,
JC−C−C−C−F = 3.0 Hz), 133.7 (CH), 134.1 (C, d, JC−C−C−C−F = 3.4 Hz),
145.6 (C), 157.0 (C, d, JC−F = 247.7 Hz), 160.5 (C), 162.1 (C, d, JC−F
= 245.0 Hz), 164.8 (C); HRMS (ESI): [MH+] calcd for
C27H25F2N4O2, 475.1940; found, 475.1929.
4-[3′-[4″-(4‴-Nitrobenzoyl)piperazine-1″-carbonyl]-4′-fluo-
robenzyl]-2H-phthalazin-1-one (14). To a solution of 4-nitro-
benzoic acid (92.0 mg, 0.550 mmol) in DMF (10 mL), was added
Et3N (119 μL, 0.880 mmol), followed by HBTU (231 mg, 0.610
mmol) and the mixture was stirred at room temperature for 1 h.
Compound 7 (200 mg, 0.550 mmol) was added, and the mixture was
stirred at room temperature for a further 48 h. Water (12 mL) was
then added, followed by 1 h of stirring, after which the mixture was
cooled to 0 °C. The resulting precipitate was collected by vacuum
filtration, washed with water (4 × 20 mL), and dried in vacuo to yield
14 (239 mg, 84%) as an orange foam. NMR spectra showed a 3:2
mixture of rotamers. Only data for the major rotamer were recorded;
IR (neat): 3167, 3012, 2904, 1638, 1616, 1599, 1346, 1433, 1265,
1004, 735 cm−1; 1H NMR (400 MHz, d6-DMSO, δ): 3.23 (s, 2H),
3.38 (s, 2H), 3.57−3.86 (m, 4H), 4.39 (s, 2H), 7.21−7.34 (m, 1H),
7.35−7.53 (m, 2H), 7.69−7.79 (m, 2H), 7.79−8.05 (m, 3H), 8.25−
8.38 (m, 3H), 12.65 (s, 1H); 13C NMR (101 MHz, d6-DMSO, δ): 37.0
(CH2), 41.9 (2 × CH2), 46.9 (2 × CH2), 116.3 (CH, d, JC−C−F = 18.2
Hz), 123.8 (C, d, JC−C−F = 18.0 Hz), 124.0 (2 × CH), 125.9 (CH),
126.5 (CH), 128.3 (C), 128.8 (2 × CH), 129.4 (CH), 129.5 (C),
132.0 (CH), 132.2 (CH, d, JC−C−C−F = 8.8 Hz), 133.9 (CH), 135.3 (C,
d, JC−C−C−C−F = 3.4 Hz), 142.3 (C), 145.2 (C), 148.4 (C), 156.8 (C d,
JC−F = 245.7 Hz), 159.8 (C), 164.5 (C), 167.8 (C); HRMS (ESI):
[MNa+] calcd for C27H22FN5NaO5, 538.1497; found, 538.1488.
tert-Butyl Piperazine-4-[[(4′-chloromethyl)benzoyl]-1′car-
bonyl]-1-carboxylate (16). The reaction was carried out as
described for 14 using a solution of 4-(chloromethyl)benzoic acid
(183 mg, 1.07 mmol) in DMF (5 mL), Et3N (23.1 μL, 1.71 mmol),
and HBTU (446 mg, 1.18 mmol). Compound 15 (200 mg, 1.07
mmol) was added, and the mixture was stirred for a further 112 h.
After this, water (10 mL) was added and the crude product was
extracted into dichloromethane (3 × 10 mL). The organic layers were
combined and washed with water (6 × 20 mL), dried with MgSO4,
filtered, and concentrated in vacuo to give a white solid. Purification by
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flash column chromatography (hexane/EtOAc, 1:1) gave 16 as a white
solid (144 mg, 40%); mp 140−142 °C; IR (neat): 3003, 2881, 1681,
1622, 1568, 1426, 1349, 1263, 1012, 724, 668 cm−1; 1H NMR (400
MHz, CDCl3, δ): 1.47 (s, 9H), 3.28−3.84 (m, 8H), 4.60 (s, 2H), 7.43
(q, J = 11.9 Hz, 4H); 13C NMR (101 MHz, CDCl3, δ): 28.5 (3 ×
CH3), 43.8 (2 × CH2), 45.6 (CH2), 47.7 (2 × CH2), 80.5 (C), 127.6
(2 × CH), 128.8 (2 × CH), 135.6 (C), 139.4 (C), 154.6 (C), 170.1
(C); HRMS (ESI): [MNa+] calcd for C17H23
35Cl2N2NaO3, 361.1289;
found, 361.1273.
tert-Butyl Piperazine-4-[[(4′-fluoromethyl)benzoyl]-1′car-
bonyl]-1-carboxylate (17). To a solution of 16 (55.0 mg, 0.162
mmol) in MeCN (1.5 mL) was added a 1 M solution of TBAF (325
μL, 0.325 mmol) in tetrahydrofuran. The mixture was heated to 80 °C
and stirred for 1 h followed by evaporation of solvent in vacuo. The
crude product was extracted into dichloromethane (5 mL), and the
organic layer was washed with water (3 × 10 mL), dried with MgSO4,
filtered, and concentrated in vacuo to give 17 (52.0 mg, 100%) as a
white solid; mp 96−98 °C; IR (neat): 3013, 2928, 1690, 1630, 1420,
1250, 1009, 909, 756, 731 cm−1; 1H NMR (400 MHz, CDCl3, δ): 1.45
(s, 9H), 3.25−3.84 (m, 8H), 5.40 (d, J = 47.4 Hz, 2H), 7.37−7.43 (m,
4H); 13C NMR (101 MHz, CDCl3, δ): 28.5 (3 × CH3), 42.2 (CH2),
43.7 (2 × CH2), 47.6 (CH2), 80.5 (C), 83.9 (CH2, d, JC−F = 167.6
Hz), 127.4 (2 × CH, d, JC−C−C−F = 6.2 Hz), 127.5 (2 × CH), 135.9
(C, d, JC−C−C−C−C−F = 2.6 Hz), 138.1 (C, d, JC−C−F = 17.4 Hz), 154.6
(C), 170.2 (C); HRMS (ESI): [MNa+] calcd for C17H23FN2NaO3,
345.1585; found, 345.1569.
Piperazine-4-[(4′-fluoromethyl)benzoyl]-1′carbonyl (18). To
a solution of 17 (52.0 mg, 0.161 mmol) in dichloromethane (1 mL)
was added trifluoroacetic acid (124 μL, 1.61 mmol), and the mixture
was stirred at room temperature for 4 h. The crude product was
extracted into EtOAc (5 mL), and the organic layer was washed using
an aqueous saturated solution of potassium carbonate (3 × 10 mL),
dried with MgSO4, filtered, and concentrated in vacuo to give 18 (31.0
mg, 87%) as an orange oil; IR (neat): 3411, 3001, 2957, 1613, 1437,
1276, 1263, 1016, 748 cm−1; 1H NMR (400 MHz, CDCl3, δ): 2.80 (br
s, 2H), 2.94 (br s, 2H), 3.38 (br s, 2H), 3.75 (br s, 2H), 5.40 (d, J =
47.5 Hz, 2H), 7.38−7.45 (m, 4H); 13C NMR (101 MHz, CDCl3, δ):
43.3 (CH2), 46.0 (CH2), 46.5 (CH2), 49.0 (CH2), 84.0 (CH2, d, JC−F
= 167.4 Hz), 127.3 (2 × CH, d, JC−C−C−F = 6.4 Hz), 127.4 (2 × CH),
136.3 (C, d, JC−C−C−C−C−F = 2.8 Hz), 137.7 (C, d, JC−C−F = 17.4 Hz),
170.0 (C); HRMS (ESI): [MNa+] calcd for C12H15FN2NaO,
245.1061; found, 245.1064.
4-[3′-[4″-(4‴-Fluoromethyl)benzoyl)piperazine-1″-carbon-
yl]-4′-fluorobenzyl]-2H-phthalazin-1-one (20). To a solution of
19 (38.0 mg, 0.126 mmol) in DMF (1 mL) was added Et3N (26.0 μL,
0.189 mmol), followed by HBTU (52.6 mg, 0.139 mmol), and the
mixture was stirred at room temperature for 1 h. Compound 18 (28.0
mg, 0.126 mmol) was added, and the mixture was stirred for a further
72 h. Water (4 mL) was then added, followed by 1 h of stirring, after
which the mixture was cooled to 0 °C. The resulting precipitate was
collected by vacuum filtration, and the crude orange solid was purified
by flash column chromatography (MeOH/EtOAc, 1:19) gave 20 (10.7
mg, 17%) as a yellow foam; IR (neat): 3213, 3005, 2926, 1613, 1572,
1429, 1256, 1225, 1003, 750 cm−1; 1H NMR (400 MHz, CDCl3, δ):
3.13−4.02 (m, 8H), 4.29 (s, 2H), 5.41 (d, J = 47.3 Hz, 2H), 7.04 (br s,
1H), 7.34 (d, J = 6.2 Hz, 2H), 7.43 (br s, 4H), 7.67−7.72 (m, 1H),
7.73−7.80 (m, 2H), 8.44−8.49 (m, 1H), 10.70 (br s, 1H); 13C NMR
(101 MHz, CDCl3, δ): 37.8 (CH2), 42.3 (2 × CH2), 47.2 (2 × CH2),
84.0 (CH2, d, JC−F = 167.8 Hz), 116.3 (CH, d, JC−C−F = 19.9 Hz),
123.8 (C, d, JC−C−F = 18.2 Hz), 125.1 (CH), 127.4 (CH), 127.5 (2 ×
CH, d, JC−C−C−F = 6.0 Hz), 127.6 (2 × CH), 128.5 (C), 129.4 (CH, d,
JC−C−C−F = 3.7 Hz), 129.7 (C), 131.8 (CH), 132.0 (CH, d, JC−C−C−F =
8.2 Hz), 133.8 (CH), 134.6 (C, d, JC−C−C−C−F = 3.5 Hz), 135.5 (C, d,
JC−C−C−C−C−F = 2.8 Hz), 138.5 (C, d, JC−C−F = 17.5 Hz), 145.6 (C),
157.1 (C, d, JC−F = 247.1 Hz), 160.5 (C), 165.3 (C), 170.3 (C);
HRMS (ESI): [MNa+] calcd for C28H24F2N4NaO3, 525.1714; found,
525.1738.
4-[3′-[4″-(4‴-Chloromethyl)benzoyl)piperazine-1″-carbon-
yl]-4′-fluorobenzyl]-2H-phthalazin-1-one (21). The reaction was
carried out as described for 14 using a solution of 4-(chloromethyl)-
benzoic acid (18.7 mg, 0.110 mmol) in DMF (1 mL), Et3N (24.0 μL,
0.180 mmol) and HBTU (45.6 mg, 0.120 mmol). Following the
addition of 7 (40.0 mg, 0.110 mmol) the mixture was stirred at room
temperature for a further 72 h. Water (6 mL) was then added,
followed by 0.5 h of stirring, after which the mixture was cooled to 0
°C. The resulting precipitate was collected by vacuum filtration and
washed with water (4 × 20 mL). Purification by flash column
chromatography (MeOH/EtOAc, 1:19) gave 21 (19.0 mg, 34%) as a
white foam; IR (neat): 3200, 2924, 1630, 1429, 1256, 1005, 750, 731
cm−1; 1H NMR (400 MHz, CDCl3, δ): 3.21−3.99 (m, 8H), 4.27 (s,
2H), 4.59 (s, 2H), 7.03 (br s, 1H), 7.30−7.36 (m, 2H), 7.37−7.49 (m,
4H), 7.67−7.72 (m, 1H), 7.73−7.80 (m, 2H), 8.44−8.49 (m, 1H),
10.84 (br s, 1H); 13C NMR (101 MHz, CDCl3, δ): 37.8 (CH2), 42.3
(2 × CH2), 45.6 (CH2), 47.1 (2 × CH2), 116.3 (CH, d, JC−C−F = 19.9
Hz), 123.8 (C, d, JC−C−F = 17.7 Hz), 125.1 (CH), 127.4 (CH), 127.7
(2 × CH), 128.5 (C), 129.0 (2 × CH), 129.4 (CH, d, JC−C−C−F = 3.6
Hz), 129.7 (C), 131.8 (CH), 132.0 (CH, d, JC−C−C−F = 8.2 Hz), 132.1
(2 × CH), 133.8 (CH), 134.6 (C, d, JC−C−C−C−F = 3.5 Hz), 135.2 (C),
139.7 (C), 145.6 (C), 157.2 (C, d, JC−F = 248.1 Hz), 160.5 (C), 165.3
(C), 170.2 (C); HRMS (ESI): [MNa+] calcd for C28H24
35ClFN4NaO3,
541.1413; found, 541.1413.
4-[3′-[4″-(4‴-Chloromethyl)benzoyl)piperazine-1″-carbon-
yl]-4′-fluorobenzyl]-2-tert-butyloxycarbonylphthalazin-1-one
(22). To a solution of 21 (170 mg, 0.328 mmol) in MeCN (1.5 mL)
was added di-tert-butyl dicarbonate (86.0 mg, 0.393 mmol) and
DMAP (4.00 mg, 0.0328 mmol). The mixture was stirred at room
temperature for 4 h followed by the evaporation of solvent in vacuo.
The crude product was extracted into EtOAc (5 mL), and the organic
layer was washed with water (3 × 10 mL), dried with MgSO4, filtered
and concentrated in vacuo to give 22 as a white foam (148 mg, 72%);
IR (neat): 2982, 1634, 1427, 1248, 1003, 750 cm−1; 1H NMR (400
MHz, CDCl3, δ): 1.66 (s, 9H), 3.15−3.99 (m, 8H), 4.30 (s, 2H), 4.59
(s, 2H), 7.03 (br s, 1H), 7.30−7.36 (m, 2H), 7.37−7.49 (m, 4H),
7.59−7.67 (m, 1H), 7.69−7.78 (m, 2H), 8.42−8.49 (m, 1H); 13C
NMR (101 MHz, CDCl3, δ): 27.8 (3 × CH3), 38.1 (CH2), 42.2 (2 ×
CH2), 45.4 (CH2), 47.1 (2 × CH2), 85.9 (C), 116.2 (CH, d, JC−C−F =
20.4 Hz), 123.7 (C, d, JC−C−F = 18.2 Hz), 125.1 (CH), 127.6 (2 ×
CH), 128.1 (CH), 128.7 (C), 128.8 (2 × CH), 129.1 (C), 129.2 (CH,
d, JC−C−C−F = 3.4 Hz), 131.8 (CH, d, JC−C−C−F = 7.6 Hz), 132.0 (CH),
134.0 (CH), 134.1 (C, d, JC−C−C−C−F = 3.7 Hz), 135.1 (C), 139.5 (C),
145.3 (C), 151.1 (C), 157.0 (C, d, JC−F = 247.7 Hz), 158.2 (C), 165.1
(C), 170.0 (C); HRMS (ESI): [MNa+] calcd for C33H32
35ClFN4NaO5,
641.1937; found, 641.1915.
In Vitro Characterization. Lipophilicity (log Poct) and percentage
plasma protein binding values and the cell-free IC50 parameter for
compounds 8−13 and 20 were obtained using previously described
HPLC and colorimetric dose−response methodologies, respectively.19
Similarly, the cellular IC50 parameter of 8 and 20 and the plasma
stability and intrinsic clearance parameters of compound 20 were
established using previously reported methods.19 Correlation of
cellular fluorescence IC50 data with cell-free colorimetric IC50 data
was used to eliminate potential fluorescence assay interference
mechanisms.
Generation of 18F−/H2
18O. [18F]fluoride was generated via the
[18O(p, n)18F] nuclear reaction by irradiating [18O]water using a 16.5
MeV proton beam (40 μA) produced by a PETtrace 6 cyclotron unit.
Manual Radiosynthesis of [18F]8. A stock solution of K222/
K2CO3 (0.25 mL), prepared by dissolving 100.0 mg of K222 (0.266
mmol) in 2 mL of MeCN and adding 12.0 mg of K2CO3 (0.087
mmol) in 0.5 mL of distilled water, was added to a 2 mL v-vial
containing approximately 100 MBq of 18F−/H2
18O (0.25 mL). The
[18F]fluoride was dried by passing a constant stream of argon over the
solution at 100 °C for approximately 20 min; anhydrous MeCN was
added in three aliquots of 0.50 mL to facilitate azeotropic drying. A
solution of 14 (1.0−5.0 mg, 0.0019−0.0095 mmol) in anhydrous N-
methyl-2-pyrrolidone (0.3 mL) was then added to the v-vial, and the
reaction was allowed to proceed for 30 min at 180 °C.
Manual Radiosynthesis of [18F]20. A stock solution of 0.750 M
TBAHCO3 was prepared by diluting 2.5 mL of 1.5 M TBAOH with
2.5 mL of distilled water; CO2 was bubbled through the solution for 2
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h until pH 7.7 was reached, followed by the removal of excess CO2 by
bubbling argon through the mixture until pH 9.0 was reached. The
0.750 M TBAHCO3 solution (10 μL) was added to a 2 mL v-vial
containing 469−572 MBq of 18F−/H218O (0.16 mL). The mixture was
vortexed, and the[18F]fluoride was dried by passing a constant stream
of argon over the solution at 100 °C for approximately 20 min;
anhydrous MeCN was added in three aliquots of 0.50 mL to facilitate
azeotropic drying. A solution of 22 (4.9 mg, 0.0079 mmol) in
anhydrous MeCN (0.1 mL) and tBuOH (0.2 mL) was then added to
the v-vial, and the reaction was allowed to proceed for 30 min at 110
°C. After this, distilled water was added (0.45 mL), and the reaction
was heated at 120 °C for a further 5 min. Next, the crude reaction
mixture was cooled to room temperature, purified using HPLC, and
concentrated in vacuo in an evaporator flask. The flask was rinsed with
MeCN (3 × 0.3 mL) to extract the radiolabeled compound, and the
solution was transferred to a 2 mL v-vial; the solvent was removed by
passing a constant stream of argon over the solution at 100 °C for
approximately 15 min. The radiotracer was reconstituted in up to 0.65
mL of 5% v/v DMSO in 0.9% w/v saline. The total radiosynthetic
time was 138 ± 16 min (n = 6).
HPLC Analysis and Purification of Radiotracers. All radio-
chemical yields were determined by analytical radio-HPLC of the
crude product. Radioactivity yield was determined using the measured
radioactivity of the isolated product. Analytical and preparatory Dionex
UltiMate 300 series HPLC systems with Phenomenex Synergi 4 μm
Hydro-RP 80 Å 150 mm × 4.60 mm and 150 mm × 10 mm columns,
respectively, were used. Column temperatures were set to 25 °C, and
mobile-phase flow rates were 1 and 3 mL/min for the analytical and
preparatory systems, respectively. Analytical UV detection was
performed using a UltiMate diode array detector (190−800 nm),
and radiodetection was achieved using a Berthold Technologies Flow
Star LB513 detector. Preparatory UV detection was performed using a
Knauer Advanced Scientific Instruments Smartline UV Detector 2500,
and radiodetection was achieved using a pin-diode connected to a Lab
Logic Flow-Count radiodetector. Analysis of [18F]8, [18F]20, and [18F]
23 were performed on crude reaction mixtures that were cooled to
room temperature. [18F]8 was analyzed using the following mobile-
phase conditions: 0.0−20.0 min, 30:70 A/B to 55:45 A/B; 20.0−20.5
min, 55/45 A:B to 5:95 A/B; and 20.5−25.0 min, 5:95 A/B, where A
is MeCN and B is distilled water. [18F]20 and [18F]23 was analyzed
using the following mobile-phase conditions: 0.0−15.0 min, 30:70 A/B
to 90:10; 15.0−20.0 min, 90:10 A/B; 20.0−20.5 min, 90:10 to 30:70
A/B; and 20.5−25.0 min, 30:70 A/B, where A is MeCN and B is
distilled water. Purification of [18F]20 was performed using the
following mobile-phase conditions: 0.0−3.0 min, 30:70 A/B; 3.0−30.0
min, 30:70 to 75:25 A/B; 30.0−30.1 min, 75:25 to 95:5 A/B; and
30.1−35.0 min, 95:5 A/B, where A is MeCN and B is distilled water;
the radiolabeled product was collected at approximately 13.5 min. To
confirm the identity of the radiolabeled products, the retention times
of [18F]8, [18F]20, and [18F]23 were compared with the retention
times obtained for nonradioactive 8, 20, and 23 using the same
chromatographic conditions. Because the amount of [18F]20 that was
produced fell below the sensitivity threshold of the UV detector
(<1.68 × 10−4μmol), molar activity (Ci/μmol) was calculated using
the lowest detectable amount of nonlabeled 20 established from a
calibration plot of a range of concentrations (0.001−1.000 mg/mL).
All HPLC data acquisition and analyses were carried out using the
Chromeleon 6.8 Chromatography software.
Mouse Glioblastoma Model. U87MG-Luc2 glioblastoma cell
culture and implantation procedures were performed as reported
previously.19 Briefly, U87MG-Luc2 cells were purchased commercially
from ATCC and cultured in minimum essential media that has been
supplemented with 10% w/v fetal calf serum and 2 mM L-glutamine at
37 °C and 5% v/v CO2. Unconscious female CD1 nude mice (6−11
week old; purchased from Charles River Laboratories) had 5 × 106
U87MG-Luc2 cells injected subcutaneously into the right flank. The
resulting tumor xenografts were measured and monitored visually
every 3 days, and tumor-bearing animals were used for in vivo studies
28−30 days post-implantation.
Ex Vivo Biodistribution with and without Preblockade.
Subcutaneous tumor bearing mice were administered 1.8−2.6 MBq of
[18F]20 in 0.11−0.21 mL of 5% v/v DMSO in 0.9% saline via bolus
tail-vein injections. The remainder of the experiment was conducted as
described previously.19
PET−MR Imaging. A single subcutaneous U87MG-Luc2 tumor
bearing female CD1 nude mouse was anaesthetized using inhaled
isoflurane (in medical air; induction 5% v/v; maintenance 2.0−2.5% v/
v) and placed in the nanoScan PET−MRI scanner (Mediso Medical
Imaging Systems). The mouse received a bolus tail-vein injection of
2.2 MBq of [18F]20 in 5% v/v DMSO in 0.9% saline, and a 45 min
dynamic PET scan (continuous list mode) was initiated immediately
after. This was followed by a whole-body 1T GRE 3D Cor/Sag MRI
scan. The dynamic PET data were corrected for random coincidences,
dead time, scatter, and decay and subsequently reconstructed using 3D
Tera-Tomo (Mediso). The reconstructed PET data were automatically
co-registered with the MRI data, and they were subsequently analyzed
using the PMOD 3.504 software. The PET frames from the last 15
min of the scan were summed to allow for better visual representation
of radiotracer biodistribution. Standardized uptake values (SUV) were
determined by dividing the image radiotracer concentration by the
injected dose divided by the animal weight.
Immunohistochemistry. Tumor and muscle tissue was prepared
and stained using anti-PARP-1 antibody (mouse antihuman and
mouse antibody; sc-8007; Santa Cruz), as reported previously.19
Haematoxylin and eosin and Ki67 staining were performed using a
Leica ST5020 multi-stainer. Histology images were acquired using a
Zeiss AX10 brightfield microscope at a 5× magnification.
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